Literature DB >> 29759856

Malnutrition and the Development of Periprosthetic Joint Infection in Patients Undergoing Primary Elective Total Joint Arthroplasty.

Kier Blevins1, Arash Aalirezaie1, Noam Shohat2, Javad Parvizi1.   

Abstract

BACKGROUND: Although an abundance of literature exists linking malnutrition with infectious complications in surgical patients, there is little specifically examining the link between malnutrition and periprosthetic joint infection (PJI). This study evaluated the relationship between abnormal nutritional parameters and development of PJI in patients undergoing primary total joint arthroplasty (TJA).
METHODS: We retrospectively reviewed TJA patients from 2000 to 2016 with preoperative nutritional screening at a single institution. Any development of PJI at 2 years was assessed as the primary outcome. The Musculoskeletal Infection society criteria were used to define PJI. The association between the aforementioned nutritional markers and PJI was evaluated in a bivariate analysis followed by multivariate logistic regression. Performance for markers was assessed using receiver operator characteristic curves. Sensitivity and specificity were also compared.
RESULTS: Multivariate analysis demonstrated that low albumin (adjusted odds ratio [OR], 4.69; 95% confidence interval [CI], 2.428-9.085; P < .001) and low hemoglobin (adjusted OR, 2.718; 95% CI, 1.100-2.718; P = .018) were significantly associated with PJI. Albumin had the highest specificity and (95% CI, 97.8%-98.4%) and positive predictive value compared to all other markers. Platelet-to-white blood cell ratio had the highest sensitivity (95% CI, 29.5%-40.3%). The area under the curve was greatest for albumin (0.61; 95% CI, 0.55-0.67) followed by hemoglobin (0.57; 95% CI, 0.51-0.63), platelets (0.56; 95% CI, 0.50-0.62), and platelet-to-white blood cell ratio (0.54; 95% CI, 0.49-0.60).
CONCLUSION: The most valuable predictor of PJI following primary TJA, among nutritional parameters examined, was preoperative albumin with a very high specificity and positive predictive value.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  malnutrition; outcomes; periprosthetic joint infection; risk; total joint arthroplasty

Mesh:

Substances:

Year:  2018        PMID: 29759856     DOI: 10.1016/j.arth.2018.04.027

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  6 in total

Review 1.  Contemporary Strategies to Prevent Infection in Hip and Knee Arthroplasty.

Authors:  Lachlan M Batty; Brent Lanting
Journal:  Curr Rev Musculoskelet Med       Date:  2020-08

2.  Supplementation of enteral nutritional powder decreases surgical site infection, prosthetic joint infection, and readmission after hip arthroplasty in geriatric femoral neck fracture with hypoalbuminemia.

Authors:  Yaoquan He; Jun Xiao; Zhanjun Shi; Jinwen He; Tao Li
Journal:  J Orthop Surg Res       Date:  2019-09-03       Impact factor: 2.359

3.  C-reactive protein (CRP)/albumin-to-globulin ratio (AGR) is a valuable test for diagnosing periprosthetic joint infection: a single-center retrospective study.

Authors:  Hao Wu; Liping Pan; Zhichao Meng; Heng Liu; Xin Yang; Yongping Cao
Journal:  J Orthop Traumatol       Date:  2022-08-01

4.  Serum globulin and albumin to globulin ratio as potential diagnostic biomarkers for periprosthetic joint infection: a retrospective review.

Authors:  Yongyu Ye; Weishen Chen; Minghui Gu; Guoyan Xian; Baiqi Pan; Linli Zheng; Ziji Zhang; Puyi Sheng
Journal:  J Orthop Surg Res       Date:  2020-10-07       Impact factor: 2.359

5.  The Paradox of Prosthetic Joint Infection and the Microbiome: Are Some Bacteria Actually Helpful?

Authors:  Ayesha Abdeen; Craig J Della Valle; Daniel Kendoff; Antonia F Chen
Journal:  Arthroplast Today       Date:  2022-01-18

6.  The effect of preoperative hypoalbuminemia on complications after primary hip arthroplasty.

Authors:  Yang Tan; Lingxiao Jiang; Hankun Liu; Zhengqi Pan; Hua Wang; Liaobin Chen
Journal:  J Orthop Surg Res       Date:  2021-09-15       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.